Chronic beryllium disease

Chronic beryllium disease (CBD), also known as berylliosis, is an occupational and environmental granulomatous lung disease caused by inhalation of beryllium dust, fumes, or particles. It is classified as a form of pneumoconiosis and primarily affects the lungs, though it can also involve the skin, lymph nodes, liver, and other organs. CBD develops in genetically susceptible individuals who have been exposed to beryllium, typically in occupational settings such as aerospace manufacturing, nuclear weapons production, electronics, ceramics, and dental alloy processing. The disease is characterized by a cell-mediated immune response (delayed-type hypersensitivity) to beryllium, leading to the formation of noncaseating granulomas in affected tissues, most prominently in the lungs. Key symptoms include progressive dyspnea (shortness of breath), chronic dry cough, fatigue, weight loss, chest pain, and night sweats. As the disease progresses, patients may develop restrictive or obstructive lung function impairment, reduced gas exchange capacity, and pulmonary fibrosis. The clinical and histological presentation closely resembles sarcoidosis, making differentiation challenging without a documented history of beryllium exposure and confirmatory immunologic testing. A preclinical stage known as beryllium sensitization can be detected by the beryllium lymphocyte proliferation test (BeLPT), which identifies an immune response to beryllium before clinical disease manifests. Genetic susceptibility plays a significant role in CBD development. The HLA-DPB1 gene variant encoding a glutamic acid at position 69 (Glu69) is strongly associated with increased risk of beryllium sensitization and disease. Treatment primarily involves corticosteroids (such as prednisone) to suppress the granulomatous inflammation and slow disease progression. Immunosuppressive agents such as methotrexate or azathioprine may be used as steroid-sparing therapies. Avoidance of further beryllium exposure is essential. In advanced cases with end-stage pulmonary fibrosis, lung transplantation may be considered. There is no cure for CBD, and management focuses on symptom control and slowing disease progression.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Chronic beryllium disease